Santhera and ReveraGen Announce New 2 . 5 - year Treatment Data with Vamorolone in Duchenne ...
Two leading drugs have revealed the safety, tolerability and long-term treatment benefits of a controversial muscle dystrophy drug in patients with Duchenne muscular dystrophic disorder (DMD) which have been given the green light for treatment.
Source: apnews.comPublished on 2021-04-28
Related news
- State Comptroller DiNapoli Releases Audits
- Schlumberger Launches Enterprise Data Solution
- Virtual Panel : How Open - Source is Helping to Change the World
- State Comptroller DiNapoli Releases Audits
- Evergreen partners with local Ontario conservation authority and Peel Region for next phase of AI for the Resilient City
- Planning and Statistics Authority announces policy of publishing official statistics
- State Comptroller DiNapoli Releases Audits
- PSA announces policy of publishing official statistics
- Enel X launches the first Circular City Index for Italian municipalities
- How police can use smart technology to improve community relations
- Questions and Answers on Revised EU rules on Industrial Emissions
- Staff on salaries over 100k at Watford and Hertfordshire councils | St Albans & Harpenden Review
- Santhera and ReveraGen Announce New 2 . 5 - year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy
- Digital Twins : A Comprehensive Solution or Hopeful Vision ?
- Algorithm and blues : avoiding the traps in new tech